Boswellia Serrata
Boswellia serrata, also called Indian frankincense, is a tree whose gum resin is used in supplements. Its boswellic acids, especially AKBA, inhibit the 5-lipoxygenase enzyme, part of the inflammation pathway, in lab studies. Most human trials cited here were in knee osteoarthritis. A meta-analysis of 7 small randomized trials in 545 people found less pain and stiffness and better function scores than control, but four trials tested boswellia combined with other ingredients, the three of boswellia alone were all funded by Laila (maker of 5-Loxin and Aflapin), and the authors rated trial quality medium to low. In both 5-Loxin trials, 100 mg a day did not improve function scores more than placebo. In an 8-week Evonik-funded trial in healthy adults with knee discomfort, boswellia alone lowered end-of-study pain more than placebo but did not improve WOMAC scores. Minor digestive upset was the main side effect reported.
Benefits
Knee joint comfort and stiffness
A meta-analysis of 7 randomized trials in 545 people with osteoarthritis found boswellia, alone or combined with ingredients such as curcumin or MSM, eased pain and stiffness and improved function scores more than control groups. The three trials of boswellia alone were small trials, all funded by the maker of 5-Loxin and Aflapin; results varied widely between trials, and the authors rated trial quality medium to low.
Knee swelling and inflammation markers
In a crossover trial in 30 people with knee osteoarthritis, knee swelling was less frequent on boswellia extract than on placebo. In a 120-day pilot trial of the Boswellin extract in 48 people, run by its maker, blood hs-CRP fell more than on placebo. In a 90-day trial funded by the 5-Loxin maker, the cartilage-degrading enzyme MMP-3 fell in joint fluid. All three were small trials.
Branded AKBA-enriched extracts 5-Loxin and Aflapin
In a 90-day trial in 60 adults with knee osteoarthritis, 100 mg a day of 5-Loxin improved pain and stiffness scores more than placebo but not function scores, while Aflapin improved all of them. In a 30-day trial in 60 adults, Aflapin improved pain and function scores, with pain differences from day 5. The maker funded both. No cited trial compared them with ordinary boswellia extracts.
Persistent knee discomfort in otherwise healthy adults
In an 8-week trial in 120 healthy adults over 40 with persistent knee pain, funded by Evonik, which supplied the products, boswellia extract alone lowered the end-of-study pain rating, the main outcome, more than placebo, but did not improve WOMAC scores or weekly pain ratings. Boswellia combined with an omega-3 product improved total WOMAC scores more than placebo.
Mechanism of action
5-lipoxygenase inhibition
AKBA, the main boswellic acid in enriched extracts, is reported to inhibit 5-lipoxygenase, an enzyme in the body's inflammation pathway. This comes from laboratory research described by the extract makers; no cited human study measured 5-lipoxygenase activity.
Lower cartilage-degrading enzyme in joint fluid
In the 90-day 5-Loxin trial, MMP-3, an enzyme that breaks down cartilage, fell in the joint fluid of treated people, and the same group's lab work found Aflapin inhibits MMP-3. Cartilage itself was not measured, so this does not show joint protection.
Clinical trials
Systematic review and meta-analysis of 7 randomized controlled trials of Boswellia serrata or its extracts versus placebo or other comparators in osteoarthritis; outcomes were VAS pain, WOMAC pain, stiffness and function and the Lequesne index. (Yu et al. 2020, BMC Complement Med Ther)
545 people with osteoarthritis across 7 trials.
Boswellia lowered VAS pain (WMD -8.33, 95% CI -11.19 to -5.46) and improved WOMAC pain, stiffness and function and the Lequesne index compared with control. The authors recommended at least 4 weeks of use. The trials were small, four of the seven tested boswellia combined with other ingredients such as curcumin or MSM, two compared it with ibuprofen or glucosamine rather than placebo, and three were funded by the maker of 5-Loxin and Aflapin. Results varied widely between trials, and the authors rated trial quality medium to low.
Double-blind randomized placebo-controlled trial of 5-Loxin 100 mg or 250 mg a day for 90 days, with pain and function scored on VAS, Lequesne and WOMAC scales. Run at Alluri Sitarama Raju Academy of Medical Sciences, a hospital in Eluru, India. Funded by Laila Impex R&D Center, the maker's research arm; three authors were its employees and three others were consultants to it. (Sengupta et al. 2008, Arthritis Res Ther)
75 adults with knee osteoarthritis (25 per group); 70 finished.
250 mg a day improved VAS pain, the Lequesne index and WOMAC pain, stiffness and function scores more than placebo, and VAS pain and WOMAC function already differed at day 7. 100 mg improved VAS pain, the Lequesne index and WOMAC pain more than placebo, but WOMAC stiffness and function did not differ significantly. MMP-3, a cartilage-degrading enzyme, fell in joint fluid. Minor side effects were reported about as often on placebo. Not repeated by an independent group.
Double-blind randomized placebo-controlled trial of 5-Loxin 100 mg, Aflapin 100 mg (a different boswellia extract from the same company) or placebo daily for 90 days. Run at the same hospital in Eluru, India. Supported by Laila Nutraceuticals, the maker; three of the eight authors worked at Laila Impex R&D Center, although the paper declared no conflict of interest. (Sengupta et al. 2010, Int J Med Sci)
60 adults with knee osteoarthritis (20 per group); 57 finished.
100 mg 5-Loxin improved VAS pain, WOMAC pain and WOMAC stiffness more than placebo, but its Lequesne index and WOMAC function scores did not differ significantly from placebo, although the abstract reports function gains for both extracts. Aflapin improved all five scores more than placebo. Day 7 changes were reported against baseline, not placebo. Safety tests were almost unchanged compared with placebo.
Randomized, double-blind, placebo-controlled crossover trial of a Boswellia serrata extract, 8 weeks per treatment with a washout between (Kimmatkar et al. 2003, Phytomedicine)
30 people with knee osteoarthritis.
During boswellia treatment, knee pain decreased, knee flexion and walking distance increased, and knee swelling was less frequent, with significant differences from placebo. X-rays showed no change. Minor digestive side effects were reported.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Boswellia Serrata
What is the recommended dosage of Boswellia Serrata?
There is no official dose. The knee trials cited here used 100 to 250 mg a day of an AKBA-enriched branded extract (5-Loxin or Aflapin) for 30 to 90 days, or two 169 mg Boswellin tablets a day for 120 days, usually split into two doses. Check with your doctor before starting, especially if you take other medicines.
What is Boswellia Serrata used for?
Boswellia (Indian frankincense) has been studied mostly in people with knee osteoarthritis, where small trials, most funded by extract makers, found less pain and stiffness and better function scores than placebo. In one trial in healthy adults with knee discomfort, boswellia alone lowered end-of-study pain ratings more than placebo but did not improve WOMAC scores. Its boswellic acids, especially AKBA, inhibit an enzyme in the inflammation pathway in laboratory research.
How long does boswellia take to work?
The authors of a meta-analysis of the osteoarthritis trials recommended at least 4 weeks of use before judging the effect. In maker-funded trials, pain scores differed from placebo by day 7 on 250 mg of 5-Loxin and by day 5 on Aflapin.
Is Boswellia Serrata safe, and does it have side effects?
In the trials cited here (30 to 120 people each, up to 120 days), reported side effects were minor, including digestive complaints, and a meta-analysis found no difference in adverse events from control groups, although few events were reported. Trials this small and short could miss rarer or slower-developing effects. No interaction studies are cited here, so check with your doctor or pharmacist if you take prescription medicines.
What is Boswellia Serrata?
Boswellia serrata, also called Indian frankincense, is a tree whose gum resin is used in supplements. Its boswellic acids, especially AKBA, inhibit the 5-lipoxygenase enzyme, part of the inflammation pathway, in lab studies. Most human trials cited here were in knee osteoarthritis.
Does Boswellia Serrata interact with any medications?
Possible interactions include: NSAIDs and aspirin: no cited study tested taking them together or cutting an NSAID dose, so do not change a prescribed medicine without talking to your doctor. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Boswellia Serrata?
NutraSmarts rates the evidence for Boswellia Serrata as Moderate (3 out of 5). It is backed by 4 study summaries and 8 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(8 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10(4):R85. doi: 10.1186/ar2461.PubMedUsed to support: Randomized double-blind placebo-controlled trial in 75 adults with knee osteoarthritis: 5-Loxin (30% AKBA) at 250 mg a day for 90 days improved all pain, stiffness and function scores more than placebo; 100 mg improved pain scores and the Lequesne index but not WOMAC stiffness or function; synovial fluid MMP-3 fell. Run at a hospital in Eluru, India, funded by Laila Impex R&D Center with Laila employees among the authors.
- Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. 2010;7(6):366-77. doi: 10.7150/ijms.7.366.PubMedUsed to support: Randomized double-blind placebo-controlled trial in 60 adults with knee osteoarthritis: 100 mg a day of 5-Loxin for 90 days improved VAS pain, WOMAC pain and WOMAC stiffness more than placebo but not the Lequesne index or WOMAC function; Aflapin 100 mg improved all five. Supported by Laila Nutraceuticals, with three authors at Laila Impex R&D Center.
- Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. Phytomedicine. 2003;10(1):3-7. doi: 10.1078/094471103321648593.PubMedUsed to support: Randomized double-blind placebo-controlled crossover trial in 30 people with knee osteoarthritis, 8 weeks per treatment: boswellia extract reduced knee pain and swelling frequency and increased knee flexion and walking distance versus placebo; minor digestive side effects.
- Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20(1):225. doi: 10.1186/s12906-020-02985-6.PubMedUsed to support: Meta-analysis of 7 randomized trials (545 people with osteoarthritis), four testing boswellia combined with other ingredients and two using ibuprofen or glucosamine as the comparator: boswellia and its extracts lowered VAS pain (WMD -8.33), WOMAC pain, stiffness and function and the Lequesne index versus control; recommended treatment of at least 4 weeks. Heterogeneity was high (I2 93 to 99% for VAS and WOMAC outcomes), the authors rated trial quality as generally medium to low, and the three trials of boswellia alone were all funded by the maker of 5-Loxin and Aflapin. Adverse events did not differ between groups (RR 0.63, 95% CI 0.22 to 1.83), but three of the five trials reporting them had no events in either arm.
- Comparative Effectiveness of Nutritional Supplements in the Treatment of Knee Osteoarthritis: A Network Meta-Analysis. Nutrients. 2025;17(15):2547. doi: 10.3390/nu17152547.PubMedUsed to support: Network meta-analysis of 39 RCTs (4,599 people with knee osteoarthritis) comparing eggshell membrane, vitamin D, boswellia, curcumin, ginger, krill oil and collagen with placebo. Boswellia improved WOMAC pain, stiffness and function and VAS pain versus placebo and ranked highest of the seven by SUCRA for WOMAC pain, stiffness and function and VAS pain. The rankings rested on indirect comparisons (no head-to-head trials and no closed loops), six of the eight trials in the boswellia group tested products from the maker of 5-Loxin and Aflapin and two tested multi-herb blends, funnel plots suggested publication bias or small-study effects, no certainty rating was reported, and the authors wrote that boswellia's top ranking relies heavily on weaker evidence. Adverse events were summarized narratively, with no boswellia trial among those reporting supplement-related events.
- A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8(7):615-22. doi: 10.7150/ijms.8.615.PubMedUsed to support: Double-blind placebo-controlled 30-day trial of Aflapin 100 mg a day (a boswellia extract from the same maker as 5-Loxin, not 5-Loxin itself) in 60 adults with knee osteoarthritis: VAS pain, Lequesne index and WOMAC pain, stiffness and function scores improved more than placebo by day 30, and VAS and Lequesne scores differed from placebo by day 5. Funded by Laila Impex R&D Center.
- A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytother Res. 2019;33(5):1457-1468. doi: 10.1002/ptr.6338.PubMedUsed to support: Double-blind placebo-controlled 120-day trial of the Boswellin extract (two 169.33 mg tablets a day) in 48 adults with knee osteoarthritis (42 finished): WOMAC scores, VAS pain and six-minute walk distance improved more than placebo, and serum hs-CRP fell more than placebo. All authors worked for Sami Labs or Sabinsa, which make Boswellin.
- Efficacy of Boswellia serrata Extract and/or an Omega-3-Based Product for Improving Pain and Function in People Older Than 40 Years with Persistent Knee Pain: A Randomized Double-Blind Controlled Clinical Trial. Nutrients. 2023;15(17):3848. doi: 10.3390/nu15173848.PubMedUsed to support: Four-arm double-blind 8-week trial in 120 healthy adults over 40 with persistent knee pain (boswellia extract, an omega-3 product, both, or placebo), funded by Evonik, which supplied the products and employed two of the authors. Boswellia alone lowered the end-of-study VAS pain score, the primary outcome, more than placebo (mean difference -1.78 cm, p=0.003), but did not improve WOMAC scores or weekly pain ratings more than placebo; the combination improved total WOMAC, WOMAC pain and function scores more than placebo. Mild adverse events, mostly digestive, were judged unrelated to the products.